Drug Profile
Autologous CD4+CD25hiFoxP3+regulatory T cells - iReg Medical
Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator iReg Medical
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Transplant rejection (Prevention) in Sweden (unspecified route) before September 2023
- 28 Jul 2018 No recent reports of development identified for preclinical development in Transplant-rejection(Prevention) in Sweden
- 11 Jul 2016 Preclinical development is ongoing in Sweden